Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 19, 2026Journal of Advanced ResearchOpen Access

Synthesis of scarless circular RNAs expressing long-acting GLP-1RAs for type 2 diabetes therapy

View Full Paper
Ask AI
Bookmark
Share

Authors

YLYude LinZHZhibo HuangZXZhiwei Xiao

Discussion

Loading...

Member takes

Overview

Randomized trial synthesizes long-acting circRNA expressing GLP-1RA in type 2 diabetes, suggesting new therapeutic potentials.

Key Points

  • The aim is to design and synthesize scarless circular RNAs encoding GLP-1 receptor agonists for type 2 diabetes treatment.
  • Developed a scarless PIE (SLPIE) system for RNA circularization and optimization of translational efficiency.
  • Synthesized circRNA expressing long-acting GLP-1RA and assessed efficacy in diabetic mouse models.
  • Established scalable production in an RNase III-deficient E. coli strain.
  • Scarless circRNAs encoding GLP-1 or GLP-1_FcBO showed significant hypoglycemic effects over 7 days.
  • Efficacy matched that of Semaglutide, demonstrating potent anti-obesity effects as well.
  • Incorporating 5-7% m⁶A modification improved translation with lipid nanoparticles.

Cite This Study

Lin et al. (2026) studied this question.

synapsesocial.com/papers/6a0bfda5166b51b53d378e37https://doi.org/10.1016/j.jare.2026.05.028
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Harnessing the Loop: The Perspective of Circular RNA in Modern Therapeutics2025
  2. 2Intratumoral administration of engineered circRNAs encoding cytosine deaminase-uracil phosphoribosyltransferase (CDUPRT) and IL-15 elicit superior antitumor efficacy2025
  3. 3In Silico discovery and design of molecular glues as a new strategy for development of non-peptidic, small-molecule agonists of GLP-1 receptor2025
  4. 4An Insight into Pharmaceutical Design and Pharmacokinetic Characteristics of GLP-1 RAs2025 · 5 citations
  5. 5Gut Delivery of Pentameric GLP-1 Using Genetically Engineered Bacillus subtilis for Diabetes and Obesity Treatment2025